Aeglea BioTherapeutics Investor Presentation Deck

Spyre is unique in its portfolio approach evaluating multiple combination regimens SPYRE ONLY KNOWN PORTFOLIO WITH ¤4ß7, TL1A, AND IL-23 POTENTIAL TO ADDRESS ORTHOGONAL BIOLOGY FAVORABLE TARGET PRODUCT PROFILE WITH UNIFIED Q8-12W SC DOSING ACROSS TARGETS 28

View entire presentation